A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MGAWN1 in Subjects With Suspected Central Nervous System Infection Due to West Nile Virus.

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MGAWN1 in Subjects With Suspected Central Nervous System Infection Due to West Nile Virus.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs MGAWN1 (Primary)
  • Indications Encephalitis; Meningitis; Paralysis; West Nile virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PARADIGM
  • Most Recent Events

    • 06 Nov 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 05 Jul 2011 Actual end date (5 July 2011) added as reported by ClinicalTrials.gov.
    • 05 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top